Galera Therapeutics Inc (OQ:GRTX)

Mar 28, 2024 07:00 am ET
Galera Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate Updates
Galera Therapeutics, Inc. (Nasdaq: GRTX), a biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results for the fourth...
Nov 14, 2023 07:00 am ET
Galera Reports Third Quarter 2023 Financial Results and Recent Corporate Updates
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced financial results...
Oct 31, 2023 07:00 am ET
Galera Announces Receipt of Type A Meeting Minutes and Strategic Update
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that it has...
Sep 18, 2023 07:00 am ET
Galera Schedules Type A Meeting with FDA to Discuss Next Steps for Avasopasem
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
Sep 05, 2023 07:00 am ET
Galera to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
Aug 14, 2023 07:00 am ET
Galera Reports Second Quarter 2023 Financial Results and Recent Corporate Updates
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
Aug 09, 2023 04:31 pm ET
Galera Receives Complete Response Letter from U.S. FDA for Avasopasem Manganese
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
Jun 05, 2023 02:15 pm ET
Galera Presents Additional Chronic Kidney Disease Data from ROMAN Trial at 2023 ASCO Annual Meeting
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
May 18, 2023 08:00 am ET
Galera Announces FDA Orphan Drug Designation Granted to Rucosopasem for Pancreatic Cancer
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
May 11, 2023 07:00 am ET
Galera Reports First Quarter 2023 Financial Results and Recent Corporate Updates
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
May 04, 2023 04:01 pm ET
Galera Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
May 01, 2023 07:00 am ET
Galera Expands Commercial Leadership Team
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
Apr 26, 2023 10:00 am ET
Galera to Present One-Year Reductions in Cisplatin-Related Chronic Kidney Disease Data from ROMAN Trial at 2023 American Society of Clinical Oncology (ASCO) Annual Meeting
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
Mar 10, 2023 07:00 am ET
Galera Announces Presentation of Supplemental Analysis of Phase 3 ROMAN Trial at European Congress on Head and Neck Oncology
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
Mar 08, 2023 07:00 am ET
Galera Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Updates
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
Feb 15, 2023 08:45 am ET
Galera Therapeutics Announces Pricing of Registered Direct Offering of $30 Million of Common Stock and Warrants
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
Feb 15, 2023 08:00 am ET
Galera Announces FDA Acceptance and Priority Review of Avasopasem NDA for Radiotherapy-Induced Severe Oral Mucositis
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
Dec 12, 2022 07:00 am ET
Galera Submits New Drug Application for Avasopasem for Severe Oral Mucositis
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
Nov 22, 2022 07:00 am ET
Galera to Present at Piper Sandler Annual Healthcare Conference
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
Nov 09, 2022 07:00 am ET
Galera Reports Third Quarter 2022 Financial Results and Recent Corporate Updates
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
Oct 26, 2022 01:40 pm ET
Galera Announces Presentation of Phase 3 ROMAN Long-term Follow-up Data at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
Sep 26, 2022 07:00 am ET
Galera to Present at 2022 American Society for Radiation Oncology (ASTRO) Annual Meeting
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
Sep 06, 2022 07:00 am ET
Galera to Participate in the H.C. Wainwright 24th Annual Global Investment Conference
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
Sep 01, 2022 07:00 am ET
Galera Appoints Eugene P. Kennedy, M.D., F.A.C.S., as Chief Medical Officer
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
Aug 09, 2022 07:00 am ET
Galera Reports Second Quarter 2022 Financial Results and Recent Corporate Updates
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
Jun 29, 2022 07:30 am ET
Galera Announces Results from Phase 1 Stage of GRECO-1 Trial of Rucosopasem with SBRT for NSCLC
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
Jun 02, 2022 07:00 am ET
Galera to Present at Jefferies Healthcare Conference
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
May 26, 2022 05:00 pm ET
Galera Announces Oral Presentation at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting Detailing Results from Phase 3 ROMAN Trial of Avasopasem
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
May 17, 2022 08:35 am ET
Thinking about buying stock in Pioneer Power Solutions, Aeye, Vertex Energy, Arcadia Biosciences, or Galera Therapeutics?
NEW YORK, May 17, 2022 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PPSI, LIDR, VTNR, RKDA, and GRTX.
May 16, 2022 07:30 am ET
Galera Reports First Quarter 2022 Financial Results and Recent Corporate Updates
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
May 16, 2022 07:00 am ET
Galera Announces Plan to Submit Avasopasem NDA by Year End
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
May 02, 2022 07:00 am ET
Galera Announces Topline Results from Phase 2a AESOP Trial of Avasopasem for Chemoradiotherapy-Induced Esophagitis
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
Apr 27, 2022 10:00 am ET
Galera to Present at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
Mar 10, 2022 07:00 am ET
Galera Reports Fourth Quarter and Full Year 2021 Financial Results and Recent Corporate Updates
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
Jan 06, 2022 07:00 am ET
Galera to Present at H.C. Wainwright BioConnect Conference
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
Dec 22, 2021 07:36 am ET
Thinking about buying stock in BioRestorative Therapies, DBV Technologies, Frontline, Galera Therapeutics, or Can Fite Biopharma?
NEW YORK, Dec. 22, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for BRTX, DBVT, FRO, GRTX, and CANF.
Dec 21, 2021 08:31 am ET
Thinking about buying stock in Prelude Therapeutics, Miniso Group, Galera Therapeutics, Spruce Biosciences, or Purple Innovation?
NEW YORK, Dec. 21, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for PRLD, MNSO, GRTX, SPRB, and PRPL.
Dec 20, 2021 09:55 am ET
Thinking about buying stock in Galera Therapeutics, Nio, Oragenics, Spruce Biosciences, or Occidental Petroleum?
NEW YORK, Dec. 20, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GRTX, NIO, OGEN, SPRB, and OXY.
Dec 16, 2021 09:45 am ET
Thinking about buying stock in Kaixin Auto, Stryve Foods, Powerbridge Technologies, Briacell Therapeutics, or Galera Therapeutics?
NEW YORK, Dec. 16, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for KXIN, SNAX, PBTS, BCTX, and GRTX.
Dec 15, 2021 07:30 am ET
Thinking about buying stock in Galera Therapeutics, Mesoblast, SeaChange International, American Virtual Cloud Technologies, or Biofrontera?
NEW YORK, Dec. 15, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GRTX, MESO, SEAC, AVCT, and BFRI.
Dec 14, 2021 07:30 am ET
Thinking about buying stock in Galera Therapeutics, Terminix Global, Aeglea Bio Therapeutics, Alzamend Neuro, or Selecta Biosciences?
NEW YORK, Dec. 14, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for GRTX, TMX, AGLE, ALZN, and SELB.
Dec 14, 2021 07:00 am ET
Galera Announces Primary Endpoint Met Statistical Significance in Corrected Topline Efficacy Data of Phase 3 ROMAN Trial of Avasopasem
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy (RT) in cancer, today...
Nov 15, 2021 07:00 am ET
Galera to Present at Two Upcoming Investor Conferences in November
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
Nov 10, 2021 07:00 am ET
Galera Reports Third Quarter 2021 Financial Results and Recent Corporate Updates
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
Oct 19, 2021 10:49 am ET
Thinking about buying stock in FuelCell Energy, Waitr Holdings, Galera Therapeutics, Marathon Oil, or SoFi Technologies?
NEW YORK, Oct. 19, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for FCEL, WTRH, GRTX, MRO, and SOFI.
Oct 19, 2021 07:00 am ET
Galera Announces Results of Phase 3 ROMAN Trial of Avasopasem for Radiotherapy-Induced Severe Oral Mucositis
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
Oct 12, 2021 07:00 am ET
Galera Appoints Mark J. Bachleda as Chief Commercial Officer and Jennifer Evans Stacey as Chief Legal and Compliance Officer
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
Sep 14, 2021 07:00 am ET
Galera to Host Virtual Key Opinion Leader Event on Radiotherapy-Induced Severe Oral Mucositis (SOM) in Patients with Head and Neck Cancer
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
Sep 08, 2021 07:00 am ET
Galera Announces Final Results from Pancreatic Cancer Trial Showing Improvements on all Efficacy Parameters
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutic candidates that have the potential to transform radiotherapy in cancer,...
Sep 07, 2021 07:00 am ET
Galera to Present at Three Upcoming Investor Conferences in September
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
Aug 10, 2021 07:00 am ET
Galera Reports Second Quarter 2021 Financial Results and Recent Accomplishments
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
Jun 28, 2021 07:00 am ET
Galera Announces Completion of Enrollment in Pivotal 455-Patient Phase 3 Trial of Avasopasem for Severe Oral Mucositis
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
May 26, 2021 07:00 am ET
Galera to Present at the Jefferies Virtual Healthcare Conference
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
May 17, 2021 07:00 am ET
Galera Announces First Patient Dosed with GC4711 in Phase 2b GRECO-2 Trial in Patients with Pancreatic Cancer
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
May 12, 2021 04:01 pm ET
Science Translational Medicine Article Shows Galera’s Selective Dismutase Mimetic Synergizes with Radiotherapy to Ablate Tumors
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
May 11, 2021 07:00 am ET
Galera Reports First Quarter 2021 Financial Results and Recent Accomplishments
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
May 05, 2021 07:00 am ET
Galera to Participate in the BofA Securities 2021 Virtual Healthcare Conference
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
Apr 28, 2021 04:01 pm ET
Galera Announces Updated Data from its Randomized, Multicenter, Placebo-Controlled Trial in Patients with Pancreatic Cancer
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutic candidates that have the potential to transform radiotherapy in cancer,...
Mar 11, 2021 07:00 am ET
Galera Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Accomplishments
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
Mar 10, 2021 08:00 am ET
Galera Therapeutics to Present at the Oppenheimer 31st Annual Healthcare Conference
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
Nov 20, 2020 08:00 am ET
Galera Therapeutics to Participate in the Piper Sandler 32nd Annual Virtual Healthcare Conference
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
Nov 10, 2020 07:00 am ET
Galera Therapeutics Reports Third Quarter 2020 Financial Results and Provides Business Updates
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
Nov 03, 2020 08:00 am ET
Galera Therapeutics to Present at the 29th Annual Credit Suisse Virtual Healthcare Conference
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
Oct 27, 2020 03:00 pm ET
Galera Therapeutics Announces Interim Data from Pilot Phase 1/2 Trial of GC4419 in Combination with Stereotactic Body Radiation Therapy Showed Improved Overall Survival in Patients with Locally Advanc
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
Oct 23, 2020 05:00 pm ET
Galera Therapeutics Announces Positive Interim Data from First Cohort of Patients in Pilot Phase 1/2 Clinical Trial of GC4419 in Pancreatic Cancer
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
Oct 22, 2020 08:00 am ET
Galera Therapeutics Announces Dosing of First Patient in the Phase 1/2 GRECO-1 Clinical Trial of GC4711 in Combination with SBRT for Non-Small Cell Lung Cancer
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
Sep 22, 2020 08:00 am ET
Galera Therapeutics to Host Virtual KOL Event on the Treatment of Locally Advanced Pancreatic Cancer
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
Sep 16, 2020 08:00 am ET
Galera Therapeutics Announces Dosing of First Patient in a Randomized, Double-Blind Pilot Phase 2 Clinical Trial of GC4419 for COVID-19
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
Sep 14, 2020 08:00 am ET
Galera Therapeutics to Present at the Oppenheimer Fall Healthcare Life Sciences & MedTech Summit
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
Sep 08, 2020 08:00 am ET
Galera Therapeutics Announces ASTRO Late-Breaker Presentation of Topline Safety and Efficacy Data from its Double-Blind, Placebo-Controlled Phase 1b/2a Clinical Trial of GC4419 in Combination with SBR
Galera Therapeutics, Inc. (Nasdaq: GRTX), is a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer. Today,...
Aug 10, 2020 07:00 am ET
Galera Therapeutics Reports Second Quarter 2020 Financial Results and Provides Business Updates
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
Jul 30, 2020 08:00 am ET
Galera Therapeutics to Participate in Fireside Chat at 2020 BTIG Virtual Biotechnology Conference
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
Jul 13, 2020 05:46 pm ET
Galera Therapeutics Completes Enrollment of Phase 1b/2a Clinical Trial of GC4419 in Combination with Radiotherapy for Locally Advanced Pancreatic Cancer
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary small molecule therapeutics that have the potential to transform radiotherapy in cancer,...
May 29, 2020 08:00 am ET
Galera Therapeutics Announces Avasopasem Manganese Improved Markers of Chronic Kidney Disease in Patients Receiving Cisplatin
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
May 18, 2020 04:05 pm ET
Galera Therapeutics to Host Virtual KOL Event on Cisplatin-Induced Chronic Kidney Disease
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, announced...
May 13, 2020 05:19 pm ET
Galera Therapeutics Announces New Data from the Phase 2b Trial on the Effect of Avasopasem Manganese on Cisplatin-Induced Chronic Kidney Disease to be Presented at ASCO 2020 Virtual Scientific Program
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
May 12, 2020 07:00 am ET
Galera Therapeutics Reports First Quarter 2020 Financial Results and Provides Business Updates
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
May 05, 2020 08:00 am ET
Galera Therapeutics to Present at BofA Securities 2020 Health Care Conference
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
Apr 30, 2020 04:15 pm ET
Galera Therapeutics Announces Presentation of Avasopasem Manganese Data at ASCO 2020 Virtual Scientific Program
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
Apr 02, 2020 08:00 am ET
Galera Therapeutics Appoints Linda B. West to Board of Directors
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
Mar 10, 2020 07:00 am ET
Galera Therapeutics Reports Fourth Quarter and Full Year 2019 Financial Results and Recent Accomplishments
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
Feb 27, 2020 04:05 pm ET
Galera Therapeutics Announces Avasopasem Manganese (GC4419) Maintained Anti-Cancer Benefit of Chemoradiotherapy for Head and Neck Cancer While Substantially Reducing Radiation-Induced Severe Oral Muco
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
Feb 24, 2020 08:00 am ET
Galera Therapeutics Announces Presentation of Avasopasem Manganese (GC4419) Two-Year Tumor Outcomes Data at 2020 Multidisciplinary Head and Neck Cancers Symposium
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
Feb 19, 2020 08:00 am ET
Galera Therapeutics to Present at Cowen and Company 40th Annual Health Care Conference
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
Jan 07, 2020 04:40 pm ET
Galera Therapeutics Announces Dosing of First Patient in Phase 2a Clinical Trial of Avasopasem Manganese (GC4419) in Second Indication
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
Dec 10, 2019 07:00 am ET
Galera Therapeutics Reports Third Quarter 2019 Financial Results and Provides Business Update
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
Dec 05, 2019 05:18 pm ET
Galera Therapeutics Announces Publication of GC4419 Data in the Journal of Clinical Oncology
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...
Nov 06, 2019 07:26 pm ET
Galera Therapeutics Announces Pricing of Initial Public Offering
Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today...

Thank you for visiting InsiderTracking.com. We have detected you cannot see ads being served on our site due to blocking. Unfortunately, due to the high cost of data, we cannot serve the requested page without the accompanied ads.

If you wish to consider using a browser that blocks ads, please log in or subscribe.

Alternatively, if you have installed ad-blocking software, please disable it (sometimes a complete uninstall is necessary). If you are in private browsing mode and do not want to subscribe, please disable tracking protection while visiting our website.

Thank you for using Insider Tracking.